FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1506777089> ?p ?o ?g. }

• W1506777089 abstract "Hepatocellular carcinoma (HCC) results in more than 600,000 deaths per year. Transarterial embolisation (TAE) and transarterial chemoembolisation (TACE) have become standard loco-regional treatments for unresectable HCC.To assess the beneficial and harmful effects of TACE or TAE.We searched The Cochrane Hepato-Biliary Group Controlled Trials Register, The Cochrane Cancer Network register, The Cochrane Central Register of Controlled Trials (CENTRAL) in The Cochrane Library, MEDLINE, EMBASE, Science Citation Index Expanded, and The Latin American Caribbean Health Sciences Literature (LILACS) from dates of inceptions up to September 2010.We considered for inclusion all randomised trials that compared TACE or TAE versus placebo, sham, or no intervention. Co-interventions were allowed if comparable between intervention groups. Trials with inadequate randomisation were excluded.For all-cause mortality, we calculated the log hazard ratio (HR) with standard error as point estimate and pooled them for meta-analysis using the inverse variance method. Sub-group analyses were performed regarding intervention regimen, trial truncation, or co-interventions. We validated the results with trial sequential analyses. We used random-effects model in all meta-analyses in anticipation of statistical heterogeneity among the trials.We included nine trials with 645 participants. Six trials assessed TACE versus control and three trials assessed TAE versus control. Seven trials had low risk of selection bias based on adequate generation of allocation sequence and concealment - but all these trials had other risks of bias. Three trials were stopped early due to interim inspections and one due to slow accrual. For all-cause mortality, statistical heterogeneity between trials was low to moderate (I(2)= 30%). Meta-analysis of trials with low risk of selection bias showed that TACE or TAE versus control does not significantly increase survival (HR 0.88; 95% CI 0.71 to 1.10). Two trials with low risk of selection bias, no early stopping, and no co-intervention did not establish any significant effect of TACE or TAE on overall survival (hazard ratio 1.22, 95% confidence interval 0.82 to 1.83; P = 0.33). Trial sequential analysis confirmed the absence of evidence for a beneficial effect of TACE or TAE on survival indicating the need for future randomisation of up to 383 additional participants. Substantial differences in criteria for assessing tumour response did not allow quantitative analyses. One trial investigated quality of life but did not detect any significant differences between the intervention groups. A range of adverse events including post-embolisation syndrome and serious complications were reported.There is no firm evidence to support or refute TACE or TAE for patients with unresectable HCC. More adequately powered and bias-protected trials are needed." @default.
• W1506777089 created "2016-06-24" @default.
• W1506777089 creator A5014755004 @default.
• W1506777089 creator A5019275846 @default.
• W1506777089 creator A5068012182 @default.
• W1506777089 date "2011-03-16" @default.
• W1506777089 modified "2023-10-16" @default.
• W1506777089 title "Transarterial (chemo)embolisation for unresectable hepatocellular carcinoma" @default.
• W1506777089 cites W1537940374 @default.
• W1506777089 cites W1598602811 @default.
• W1506777089 cites W1600041372 @default.
• W1506777089 cites W1670652180 @default.
• W1506777089 cites W1964489041 @default.
• W1506777089 cites W1965768884 @default.
• W1506777089 cites W1971441597 @default.
• W1506777089 cites W1973514550 @default.
• W1506777089 cites W1975154077 @default.
• W1506777089 cites W1981501248 @default.
• W1506777089 cites W1982879484 @default.
• W1506777089 cites W1986215651 @default.
• W1506777089 cites W2011897106 @default.
• W1506777089 cites W2017298531 @default.
• W1506777089 cites W2019607817 @default.
• W1506777089 cites W2020215421 @default.
• W1506777089 cites W2022705346 @default.
• W1506777089 cites W2024029636 @default.
• W1506777089 cites W2039621565 @default.
• W1506777089 cites W2042470623 @default.
• W1506777089 cites W2042803707 @default.
• W1506777089 cites W2047853874 @default.
• W1506777089 cites W2049852456 @default.
• W1506777089 cites W2051556928 @default.
• W1506777089 cites W2052552898 @default.
• W1506777089 cites W2055469806 @default.
• W1506777089 cites W2059725337 @default.
• W1506777089 cites W2062497504 @default.
• W1506777089 cites W2069029442 @default.
• W1506777089 cites W2074333538 @default.
• W1506777089 cites W2074423543 @default.
• W1506777089 cites W2075642745 @default.
• W1506777089 cites W2076539243 @default.
• W1506777089 cites W2080321731 @default.
• W1506777089 cites W2082942950 @default.
• W1506777089 cites W2088095316 @default.
• W1506777089 cites W2098195152 @default.
• W1506777089 cites W2101322147 @default.
• W1506777089 cites W2102696978 @default.
• W1506777089 cites W2103637700 @default.
• W1506777089 cites W2107328434 @default.
• W1506777089 cites W2110970000 @default.
• W1506777089 cites W2115253754 @default.
• W1506777089 cites W2115754856 @default.
• W1506777089 cites W2117294447 @default.
• W1506777089 cites W2125763116 @default.
• W1506777089 cites W2126919203 @default.
• W1506777089 cites W2126930838 @default.
• W1506777089 cites W2127772814 @default.
• W1506777089 cites W2131212067 @default.
• W1506777089 cites W2134338262 @default.
• W1506777089 cites W2137052325 @default.
• W1506777089 cites W2137493748 @default.
• W1506777089 cites W2139248078 @default.
• W1506777089 cites W2145719202 @default.
• W1506777089 cites W2150452425 @default.
• W1506777089 cites W2155802182 @default.
• W1506777089 cites W2157823046 @default.
• W1506777089 cites W2160795579 @default.
• W1506777089 cites W2161095279 @default.
• W1506777089 cites W2171673899 @default.
• W1506777089 cites W2315948693 @default.
• W1506777089 cites W2321119966 @default.
• W1506777089 cites W2329554390 @default.
• W1506777089 cites W2885316145 @default.
• W1506777089 cites W4214559180 @default.
• W1506777089 cites W4231209896 @default.
• W1506777089 cites W4243625103 @default.
• W1506777089 cites W4245792244 @default.
• W1506777089 doi "https://doi.org/10.1002/14651858.cd004787.pub2" @default.
• W1506777089 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/21412886" @default.
• W1506777089 hasPublicationYear "2011" @default.
• W1506777089 type Work @default.
• W1506777089 sameAs 1506777089 @default.
• W1506777089 citedByCount "163" @default.
• W1506777089 countsByYear W15067770892012 @default.
• W1506777089 countsByYear W15067770892013 @default.
• W1506777089 countsByYear W15067770892014 @default.
• W1506777089 countsByYear W15067770892015 @default.
• W1506777089 countsByYear W15067770892016 @default.
• W1506777089 countsByYear W15067770892017 @default.
• W1506777089 countsByYear W15067770892018 @default.
• W1506777089 countsByYear W15067770892019 @default.
• W1506777089 countsByYear W15067770892020 @default.
• W1506777089 countsByYear W15067770892021 @default.
• W1506777089 countsByYear W15067770892022 @default.
• W1506777089 countsByYear W15067770892023 @default.
• W1506777089 crossrefType "journal-article" @default.
• W1506777089 hasAuthorship W1506777089A5014755004 @default.
• W1506777089 hasAuthorship W1506777089A5019275846 @default.
• W1506777089 hasAuthorship W1506777089A5068012182 @default.
• W1506777089 hasConcept C126322002 @default.

• next